Summary

The 7 major myelodysplastic syndrome markets reached a value of US$ 2.3 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 4.5 Billion by 2034, exhibiting a growth rate (CAGR) of 6.25% during 2024-2034.

The myelodysplastic syndrome market has been comprehensively analyzed in IMARC's new report titled "Myelodysplastic Syndrome Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Myelodysplastic syndrome (MDS) refers to a type of blood cancer that occurs when immature blood cells in the bone marrow do not mature properly. Instead, they accumulate in the bone marrow, leading to a shortage of normal blood cells in the body. The common symptoms of the ailment include fatigue, weakness, shortness of breath, pale skin, dizziness, increased susceptibility to infections, etc. Some patients may also experience abnormal bruising or bleeding, such as frequent nosebleeds, bleeding gums, heavy menstrual bleeding, etc. The diagnosis of myelodysplastic syndrome typically begins with a physical exam and a review of the individual's medical history and symptoms. Blood tests are usually the first step in diagnosing MDS, as they can reveal abnormalities in the levels of blood cells present in the circulation. Various additional procedures are also ordered to confirm the diagnosis and determine the subtype of the disease. These tests include a bone marrow biopsy, in which a small sample of bone marrow is extracted and examined under a microscope to look for abnormal cells.

The rising cases of genetic mutations in the blood-forming cells of the bone marrow are primarily driving the myelodysplastic syndrome market. In addition to this, the widespread adoption of several growth factors, such as erythropoietin and granulocyte colony-stimulating factor (G-CSF), for increasing the production of blood cells in the bone marrow is acting as another significant growth-inducing factor. Furthermore, the escalating demand for hypomethylating agents, which block the activity of enzymes that inhibit the formation of blood cells in the bone marrow, thereby reducing the need for blood transfusions, is creating a positive outlook for the market. Moreover, the ongoing development of several targeted therapies, including drugs targeting the enzyme IDH1, which is mutated in a subset of MDS patients, is also augmenting the market growth. This approach allows for more precise and effective treatment with fewer side effects compared to traditional chemotherapy. Additionally, the emerging popularity of cytogenetic testing for identifying chromosome abnormalities, such as deletions, additions, or translocations, that further aid in determining the subtype of MDS is expected to drive the myelodysplastic syndrome market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the myelodysplastic syndrome market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for myelodysplastic syndrome and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the myelodysplastic syndrome market in any manner.

Time Period of the Study

Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034

Countries Covered

United States
Germany
France
United Kingdom
Italy
Spain
Japan

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario
Historical, current, and future performance of the myelodysplastic syndrome market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the myelodysplastic syndrome market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current myelodysplastic syndrome marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:
Market Insights

How has the myelodysplastic syndrome market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the myelodysplastic syndrome market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the myelodysplastic syndrome market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?

Epidemiology Insights

What is the number of prevalent cases (2018-2034) of myelodysplastic syndrome across the seven major markets?
What is the number of prevalent cases (2018-2034) of myelodysplastic syndrome by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of myelodysplastic syndrome by gender across the seven major markets?
What is the number of prevalent cases (2018-2034) of myelodysplastic syndrome by type across the seven major markets?
How many patients are diagnosed (2018-2034) with myelodysplastic syndrome across the seven major markets?
What is the size of the myelodysplastic syndrome patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of myelodysplastic syndrome?
What will be the growth rate of patients across the seven major markets?

Myelodysplastic Syndrome: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for myelodysplastic syndrome drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the myelodysplastic syndrome market?
What are the key regulatory events related to the myelodysplastic syndrome market?
What is the structure of clinical trial landscape by status related to the myelodysplastic syndrome market?
What is the structure of clinical trial landscape by phase related to the myelodysplastic syndrome market?
What is the structure of clinical trial landscape by route of administration related to the myelodysplastic syndrome market?

ページTOPに戻る

Table of Contents

​1 Preface

2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Myelodysplastic Syndrome - Introduction
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence

5 Myelodysplastic Syndrome - Disease Overview
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment

6 Patient Journey

7 Myelodysplastic Syndrome - Epidemiology and Patient Population
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Epidemiology by Type (2018-2034)
7.2.6 Diagnosed Cases (2018-2034)
7.2.7 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Epidemiology by Type (2018-2034)
7.3.6 Diagnosed Cases (2018-2034)
7.3.7 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Epidemiology by Type (2018-2034)
7.4.6 Diagnosed Cases (2018-2034)
7.4.7 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Epidemiology by Type (2018-2034)
7.5.6 Diagnosed Cases (2018-2034)
7.5.7 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Epidemiology by Type (2018-2034)
7.6.6 Diagnosed Cases (2018-2034)
7.6.7 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Epidemiology by Type (2018-2034)
7.7.6 Diagnosed Cases (2018-2034)
7.7.7 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Epidemiology by Type (2018-2034)
7.8.6 Diagnosed Cases (2018-2034)
7.8.7 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Epidemiology by Type (2018-2034)
7.9.6 Diagnosed Cases (2018-2034)
7.9.7 Patient Pool/Treated Cases (2018-2034)

8 Myelodysplastic Syndrome - Treatment Algorithm, Guidelines, and Medical Practices
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm

9 Myelodysplastic Syndrome - Unmet Needs

10 Myelodysplastic Syndrome - Key Endpoints of Treatment

11 Myelodysplastic Syndrome - Marketed Products
11.1 List of Myelodysplastic Syndrome Marketed Drugs Across the Top 7 Markets
11.1.1 Gleevec (Imatinib) - Novartis
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Revlimid (Lenalidomide) - Celgene Corporation
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Vidaza (Azacitidine) - Pfizer
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
11.1.4 Inqovi (Cedazuridine/decitabine) - Astex Pharmaceuticals
11.1.4.1 Drug Overview
11.1.4.2 Mechanism of Action
11.1.4.3 Regulatory Status
11.1.4.4 Clinical Trial Results
11.1.4.5 Sales Across Major Markets
11.1.5 Reblozyl (Luspatercept) - Acceleron Pharma/Celgene Corporation
11.1.5.1 Drug Overview
11.1.5.2 Mechanism of Action
11.1.5.3 Regulatory Status
11.1.5.4 Clinical Trial Results
11.1.5.5 Sales Across Major Markets

Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.

12 Myelodysplastic Syndrome - Pipeline Drugs
12.1 List of Myelodysplastic Syndrome Pipeline Drugs Across the Top 7 Markets
12.1.1 Venetoclax - AbbVie/Genentech
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 CTX-712 - Chordia Therapeutics
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 AK117 - Akeso Biopharma
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 Evorpacept - ALX Oncology
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 sabatolimab - Novartis Oncology
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status

Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.

13. Myelodysplastic Syndrome - Attribute Analysis of Key Marketed and Pipeline Drugs

14. Myelodysplastic Syndrome – Clinical Trial Landscape
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events

15 Myelodysplastic Syndrome - Market Scenario
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Myelodysplastic Syndrome - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Myelodysplastic Syndrome - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Myelodysplastic Syndrome - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Myelodysplastic Syndrome - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Myelodysplastic Syndrome - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Myelodysplastic Syndrome - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Myelodysplastic Syndrome - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Myelodysplastic Syndrome - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Myelodysplastic Syndrome - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Myelodysplastic Syndrome - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Myelodysplastic Syndrome - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Myelodysplastic Syndrome - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Myelodysplastic Syndrome - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Myelodysplastic Syndrome - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Myelodysplastic Syndrome - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Myelodysplastic Syndrome - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Myelodysplastic Syndrome - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Myelodysplastic Syndrome - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Myelodysplastic Syndrome - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Myelodysplastic Syndrome - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Myelodysplastic Syndrome - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Myelodysplastic Syndrome - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Myelodysplastic Syndrome - Access and Reimbursement Overview

16 Myelodysplastic Syndrome - Recent Events and Inputs From Key Opinion Leaders

17 Myelodysplastic Syndrome Market - SWOT Analysis
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats

18 Myelodysplastic Syndrome Market – Strategic Recommendations

19 Appendix